SEC Form S-8 filed by Brooklyn ImmunoTherapeutics Inc.
Delaware | | | 31-1103425 |
(State or other jurisdiction of incorporation or organization) | | | (I.R.S. Employer Identification No.) |
| | ||
1035 Cambridge Street, Suite 18A Cambridge, MA 02141 | | | 02141 |
(Address of Principal Executive Offices) | | | (Zip Code) |
Large accelerated filer | | | ☐ | | | Accelerated filer | | | ☐ |
Non-accelerated filer | | | ☒ | | | Smaller reporting company | | | ☒ |
| | | | Emerging growth company | | | ☐ |
Item 3. | Incorporation of Documents by Reference. |
Item 4. | Description of Securities. |
Item 5. | Interests of Named Experts and Counsel. |
Item 6. | Indemnification of Directors and Officers. |
Item 7. | Exemption from Registration Claimed. |
Item 8. | Exhibits. |
Exhibit Number | | | Exhibit Description | | | Filed Herewith | | | Incorporated by Reference herein from Form or Schedule | | | Filing Date | | | SEC File/ Reg. Number |
| | Composite Restated Certificate of Incorporation of the Registrant. | | | | | Form 10-K (Exhibit 3.1) | | | 03/20/2023 | | | 001-11460 | ||
| | Certificate of Validation of the Registrant. | | | | | Form 8-K (Exhibit 3.1) | | | 09/13/2021 | | | 001-11460 | ||
| | Second Amended and Restated Bylaws of the Registrant. | | | | | Form 8-K (Exhibit 3.2) | | | 10/11/2022 | | | 001-11460 | ||
| | Opinion of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. | | | X | | | | | | | ||||
| | Eterna Therapeutics Inc. Restated 2020 Stock Incentive Plan. | | | | | Form 8-K (Exhibit 99.1) | | | 09/13/2021 | | | 001-11460 | ||
| | Consent of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. (included in opinion of counsel filed Exhibit 5.1). | | | X | | | | | | | ||||
| | Consent of Grant Thornton LLP, independent registered public accounting firm. | | | X | | | | | | | ||||
| | Consent of Marcum LLP, independent registered public accounting firm. | | | X | | | | | | | ||||
| | Power of Attorney to file future amendments (set forth on the signature page of this Registration Statement). | | | X | | | | | | | ||||
| | Form of Stock Option Inducement Award. | | | X | | | | | | | ||||
| | Filing Fee Table. | | | X | | | | | | |
| | ETERNA THERAPEUTICS INC. | ||||
| | | | |||
| | By: | | | /s/ Sanjeev Luther | |
| | Sanjeev Luther | ||||
| | President and Chief Executive Officer |
Name | | | Title | | | Date |
| | | | |||
/s/ Sanjeev Luther | | | President and Chief Executive Officer (Principal Executive Officer) | | | January 16, 2024 |
Sanjeev Luther | | |||||
| | | | |||
/s/ Sandra Gurrola | | | Senior Vice President of Finance (Principal Financial and Accounting Officer) | | | January 16, 2024 |
Sandra Gurrola | | |||||
| | | | |||
/s/ James Bristol | | | Director | | | January 16, 2024 |
James Bristol | | |||||
| | | | |||
/s/ William Wexler | | | Director | | | January 16, 2024 |
William Wexler | | |||||
| | | | |||
/s/ Dorothy J. Clarke | | | Director | | | January 16, 2024 |
Dorothy J. Clarke | |